115 related articles for article (PubMed ID: 11572633)
1. Vaccination against murine gamma-herpesvirus infection.
Woodland DL; Usherwood EJ; Liu L; Flaño E; Kim IJ; Blackman MA
Viral Immunol; 2001; 14(3):217-26. PubMed ID: 11572633
[TBL] [Abstract][Full Text] [Related]
2. Natural history of murine gamma-herpesvirus infection.
Nash AA; Dutia BM; Stewart JP; Davison AJ
Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):569-79. PubMed ID: 11313012
[TBL] [Abstract][Full Text] [Related]
3. Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.
McClellan JS; Tibbetts SA; Gangappa S; Brett KA; Virgin HW
J Virol; 2004 Jul; 78(13):6836-45. PubMed ID: 15194759
[TBL] [Abstract][Full Text] [Related]
4. A replication-deficient murine gamma-herpesvirus blocked in late viral gene expression can establish latency and elicit protective cellular immunity.
Kayhan B; Yager EJ; Lanzer K; Cookenham T; Jia Q; Wu TT; Woodland DL; Sun R; Blackman MA
J Immunol; 2007 Dec; 179(12):8392-402. PubMed ID: 18056385
[TBL] [Abstract][Full Text] [Related]
5. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
[TBL] [Abstract][Full Text] [Related]
6. T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice.
Liu L; Usherwood EJ; Blackman MA; Woodland DL
J Virol; 1999 Dec; 73(12):9849-57. PubMed ID: 10559297
[TBL] [Abstract][Full Text] [Related]
7. Effective vaccination against long-term gammaherpesvirus latency.
Tibbetts SA; McClellan JS; Gangappa S; Speck SH; Virgin HW
J Virol; 2003 Feb; 77(4):2522-9. PubMed ID: 12551990
[TBL] [Abstract][Full Text] [Related]
8. Murine herpesvirus pathogenesis: a model for the analysis of molecular mechanisms of human gamma herpesvirus infections.
Rajćáni J; Kúdelová M
Acta Microbiol Immunol Hung; 2005; 52(1):41-71. PubMed ID: 15957234
[TBL] [Abstract][Full Text] [Related]
9. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination.
Stewart JP; Micali N; Usherwood EJ; Bonina L; Nash AA
Vaccine; 1999 Jan; 17(2):152-7. PubMed ID: 9987149
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection.
Aricò E; Robertson KA; Belardelli F; Ferrantini M; Nash AA
Vaccine; 2004 Mar; 22(11-12):1433-40. PubMed ID: 15063566
[TBL] [Abstract][Full Text] [Related]
11. Lytic cycle T cell epitopes are expressed in two distinct phases during MHV-68 infection.
Liu L; Flaño E; Usherwood EJ; Surman S; Blackman MA; Woodland DL
J Immunol; 1999 Jul; 163(2):868-74. PubMed ID: 10395681
[TBL] [Abstract][Full Text] [Related]
12. A gamma-herpesvirus deficient in replication establishes chronic infection in vivo and is impervious to restriction by adaptive immune cells.
Tibbetts SA; Suarez F; Steed AL; Simmons JA; Virgin HW
Virology; 2006 Sep; 353(1):210-9. PubMed ID: 16797052
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the host response to a gamma-herpesvirus.
Doherty PC; Christensen JP; Belz GT; Stevenson PG; Sangster MY
Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):581-93. PubMed ID: 11313013
[TBL] [Abstract][Full Text] [Related]
14. Early establishment of gamma-herpesvirus latency: implications for immune control.
Flaño E; Jia Q; Moore J; Woodland DL; Sun R; Blackman MA
J Immunol; 2005 Apr; 174(8):4972-8. PubMed ID: 15814726
[TBL] [Abstract][Full Text] [Related]
15. Immune evasion by gamma-herpesviruses.
Stevenson PG
Curr Opin Immunol; 2004 Aug; 16(4):456-62. PubMed ID: 15245739
[TBL] [Abstract][Full Text] [Related]
16. A mouse model for infectious mononucleosis.
Flaño E; Woodland DL; Blackman MA
Immunol Res; 2002; 25(3):201-17. PubMed ID: 12018460
[TBL] [Abstract][Full Text] [Related]
17. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages.
Flaño E; Husain SM; Sample JT; Woodland DL; Blackman MA
J Immunol; 2000 Jul; 165(2):1074-81. PubMed ID: 10878386
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated control of persistent gamma-herpesvirus infection.
Kim IJ; Flaño E; Woodland DL; Blackman MA
J Immunol; 2002 Apr; 168(8):3958-64. PubMed ID: 11937552
[TBL] [Abstract][Full Text] [Related]
19. A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
Stevenson PG; Belz GT; Castrucci MR; Altman JD; Doherty PC
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):9281-6. PubMed ID: 10430934
[TBL] [Abstract][Full Text] [Related]
20. Prospects of a novel vaccination strategy for human gamma-herpesviruses.
Wu TT; Blackman MA; Sun R
Immunol Res; 2010 Dec; 48(1-3):122-46. PubMed ID: 20717741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
